Floatz logo

Ibandronate

Pain; Bone Neoplasms; Neoplasm Metastasis

Kelly Fitzgerald, MDSmall moleculePhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Pain; Bone Neoplasms; Neoplasm Metastasis cohort.

Asset / SponsorPhaseRating
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB
TECHNETIUM TC-99M CATION, UNSPECIFIED
University of California, San Francisco
Phase 3BB

View all 50 →

Same molecule, other indications

Ibandronate is also rated in:

PainDormant
BB
Indicative ·
64 / 100
View asset →
metastatic malignant neoplasmDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →